长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌

目的 :观察长春瑞滨 (NVB)加奥沙利铂 (乐沙定 ,LOHP)治疗晚期非小细胞肺癌 (NSCLC)的疗效及毒副反应。方法 :经病理组织学或细胞学证实的 5 0例晚期非小细胞肺癌患者 ,随机分为治疗组 2 6例及对照组 2 4例 ,分别给予NVB LOHP及NVB CDDP治疗 ,2 1天为一个周期 ,均治疗 2周期以上。结果 :治疗组总有效率为 38.5 % ,对照组总有效率为 4 1.6 % (P >0 .0 5 )。毒副反应以白细胞降低、胃肠道反应和周围神经炎为主 ,而Ⅲ～Ⅳ度消化道反应、肾脏损害及心功能下降主要发生在对照组 ,周围神经炎主要发生在治疗组 (P <0 .0 5 ) ,但均可耐受。结论 :长春瑞滨 (NVB)加奥沙利铂与长春瑞滨 (NVB)加顺铂治疗晚期非小细胞肺癌相似 ,均有较好的近期疗效 ,而长春瑞滨(NVB)加奥沙利铂组的毒副反应较轻 ,临床应用更安全 ,更适合于老年患者。     

草酸铂联合卡培他滨治疗晚期胃癌的近期疗效分析

目的：探讨草酸铂联合卡培他滨治疗晚期胃癌的近期疗效。方法：对32例晚期胃癌采用草酸铂联合卡培他滨方案治疗共76周期。结果：CR6例，PR16例，NC8例和PD2例，总有效率(CR PR)为68．75％(22／32)。中位缓解期8个月，中位生存期12个月，1年生存率为55％；临床受益者共30例(93．75％)。不良反应可耐受，经积极对症治疗后均见好转，无相关死亡出现。无患者因为不良反应中止治疗。结论：草酸铂加卡培他滨方案而组成的OX方案治疗晚期胃癌疗效较好，毒性反应能够耐受，可作为经济状况好的患者的一线方案在更多的病人中应用，以进一步探讨其疗效。     

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

Background: Oxaliplatin is a new cytotoxic agent from the diaminocyclohexane family with proven antitumor activity against colon cancer cell lines. Activity in patients with colorectal carcinoma previously treated with 5-fluorouracil has been studied in three single-agent phase II trials, showing a reproducible response rate of 10%. Here we report a phase II trial with oxaliplatin as a first-line chemotherapy for metastatic colorectal cancer.Patients and methods: Twenty-five patients were entered in the study. All of them had metastatic disease without previous chemotherapy, and at least one lesion had to be measurable by computed tomography (CT). Therapy consisted of a two-hour infusion of oxaliplatin at a dose of 130 mg/m² every 21 days.Results: The overall response rate determined by investigators was 20% (95% CI, 6.8%–40.7%). Eight patients (32%) had stable disease. The median time to disease progression in responders was six months (range four to nine). The median progression-free survival was four months and median overall survival 14.5 months (95% CI, 10–20 months). The main toxic effects were peripheral neuropathy (92%) and laryngopharyngeal dysesthesia (75%). No severe grade 3–4 neurotoxicities (NCI-CTC) were found. Gastrointestinal and hematological toxicities were mild.Conclusions: Oxaliplatin is an active agent in first-line chemotherapy for advanced colorectal cancer. It was well tolerated, caused no toxic deaths, had low hematotoxicity, well controlled gastrointestinal toxicity, and frequent but mild peripheral neurological symptoms. Therefore, it is of interest to associate oxaliplatin with other active compounds.     

吉西他滨联合奥沙利铂治疗老年晚期非小细胞肺癌观察

观察吉西他滨联合奥沙利铂治疗老年晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的近期疗效及毒副反应。初治的Ⅲ~Ⅳ期老年NSCLC22例,以21d为1个周期,吉西他滨1000mg/m2,静脉滴入,d1、d8;奥沙利铂100mg/m2,静脉滴入,d1。连用2个周期后评价疗效。全组22例均可评价,有效率为40·9%(9/22),毒副反应主要为骨髓抑制及外周神经感觉异常。初步研究结果提示,吉西他滨联合奥沙利铂治疗老年晚期NSCLC有一定的疗效,毒性较小可以耐受。     

奥沙利铂联合方案治疗晚期胃癌的临床疗效

目的　研究奥沙利铂(L OHP)与氟尿嘧啶(5 FU)、亚叶酸钙(CF)联合化疗方案治疗晚期胃癌的近期疗效及不良反应。方法　2 0 0 2年6月至2 0 0 4年6月2 4例晚期胃癌患者入组本次临床试验。入组病例接受L OHP联合5 FU及CF治疗方案:d1,L OPH 130mg·m-2 ,ivgtt;d1～5 ,CF 2 0 0mg·m-2 ,ivgtt;d1～5 ,5 FU 5 0 0mg·m-2 ,ivgtt×6h ,2 1d为一个周期,至少完成3周期。分别观察其近期疗效及不良反应。结果　近期疗效判定参照WHO实体瘤疗效评价标准;不良反应按实体瘤(1981年)NCI分级标准。全组2 4例患者总有效率(CR +PR)为5 0 % (12 / 2 4 ) ;主要不良反应为轻度骨髓抑制、消化道反应及外周神经毒性。结论　L OHP联合化疗方案治疗晚期胃癌疗效确切,不良反应能耐受     

A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma

Abstract.   Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 2006; 16(Suppl. 1): 79–85
We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m²), pegylated liposomal doxorubicin (30 mg/m²), and cyclophosphamide (750 mg/m²). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients (48%). Twenty-one (53%) patients experienced grade 1–2 peripheral neuropathy. The overall response rate was 46% (95% CI 23.6–68.7). Median progression-free survival was 28 weeks (range 12–52 weeks) and median survival was 45 weeks (range 26–136+ weeks). The mean duration of response was 34 weeks (range 16–52 weeks). In platinum-resistant and -refractory ovarian cancer patients, the overall response rate was 37% (CI 95% 14.4–60.8) with a progression-free survival of 28 weeks (range 12–52 weeks) and a median survival of 42 weeks (range 28–84 weeks). This combination chemotherapy is generally well tolerated and is an active second-line regimen against ovarian cancer.     

含草酸铂方案治疗晚期贲门癌的疗效观察

目的观察草酸铂(L-OHP)联合5-氟脲嘧啶(5-Fu)、亚叶酸钙(CF)治疗晚期贲门癌的疗效与毒性。方法L-OPH135mg/m2ivgttD1,5-Fu350mg/m2ivgttD2-6,CF100mg/m2D2-6,21d为1周期。结果全组患者获得CR4例,PR12例,NC10例,PD4例,总有效率(CR+PR)为53.3%;骨髓抑制和胃肠道反应均为0-II°,80%患者出现外周感觉神经异常。结论该方案治疗晚期贲门癌疗效高,副作用少,值得临床应用。     

肠胃清粗提物协同奥沙利铂抑制人结肠癌HCT116细胞及其作用机制研究

目的 探讨中药复方肠胃清(黄芪、党参、白术、八月札、薏苡仁、野葡萄藤、大血藤、猪苓)粗提物与奥沙利铂联合应用抑制人结肠癌HCTll6细胞的协同增效作用及机理.方法 奥沙利铂、肠胃清提取物分别单独以及联合作用于人结肠癌HCTll6细胞,采用MTT法检测半数抑制质量浓度(IC50),通过TransweⅡ实验检测侵袭转移抑制作用,并利用Western Blotting技术检测侵袭转移与凋亡相关蛋白的表达变化.结果 肠胃清提取物、奥沙利铂以及联合肠胃清提取物(0.15 mg/mL)时奥沙利铂对人结肠癌HCTll6细胞的半数抑制质量浓度分别为(3.24±0.06) mg/mL、(15.74±0.53)μg/mL及(10.32±0.37)μg/mL,联合用药组半数抑制质量浓度降低,侵袭抑制率提高,ADAM-17、MMP-2、MMP-9、BCL-2蛋白表达下调(P＜0.05),P53蛋白表达升高(P＜0.01).结论 中药复方肠胃清粗提物具有一定的抗人结肠癌细胞HCTll6作用,在与奥沙利铂联用时表现出明显的协同作用,其机制可能与降低ADAM-17、M MP-2、MMP-9、BCL-2蛋白以及提高P53蛋白的表达有关.     

吉西他滨联合奥沙利铂和左旋门冬酰胺酶治疗复发性或难治性非霍奇金淋巴瘤

目的：观察吉西他滨联合奥沙利铂（L-OHP）、左旋门冬酰胺酶（L-ASP）对复发性或难治性进展型非霍奇金淋巴瘤的疗效和不良反应。方法：吉西他滨1000mg/m2,d1,d8,静脉滴注;L-OHP 80mg/m2,d1,d8,静脉滴注;L-ASP 1000 u/d,d1-d8静脉滴注。3-4周为一个化疗周期。20例复发性或难治性进展型非霍奇金淋巴瘤患者,疗程不少于3个周期。结果：20例患者中,14例获得缓解,占77.8%。其中完全缓解（CR）6例,部分缓解（PR）8例。6例具有B类症状的患者中,4例症状消失,1例明显改善,1例无改善。化疗不良作用主要为轻度的胃肠道反应,极少数患者出现严重的骨髓抑制。结论：吉西他滨联合L-OHP、L-ASP对复发性或难治性进展型非霍奇金淋巴瘤有较好的近期疗效,能明显改善患者症状,且大部分患者可以承受其不良反应,是一个值得进一步验证的补救性化疗方案。